Russell Investments Group Ltd. Invests $264,000 in Outset Medical, Inc. (NASDAQ:OM)

Russell Investments Group Ltd. purchased a new position in Outset Medical, Inc. (NASDAQ:OM) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 48,834 shares of the company’s stock, valued at approximately $264,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Nisa Investment Advisors LLC boosted its stake in Outset Medical by 1,317.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 8,790 shares of the company’s stock valued at $48,000 after buying an additional 8,170 shares in the last quarter. Valeo Financial Advisors LLC bought a new position in Outset Medical during the fourth quarter valued at about $117,000. Versor Investments LP bought a new position in Outset Medical during the third quarter valued at about $172,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Outset Medical during the third quarter valued at about $175,000. Finally, Horizon Family Wealth Inc. bought a new position in Outset Medical during the third quarter valued at about $292,000.

Insider Buying and Selling

In other Outset Medical news, CTO Jean-Olivier Racine sold 8,306 shares of the business’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $3.27, for a total value of $27,160.62. Following the completion of the transaction, the chief technology officer now directly owns 265,325 shares of the company’s stock, valued at $867,612.75. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 23,921 shares of company stock valued at $78,934 over the last three months. Company insiders own 3.50% of the company’s stock.

Outset Medical Trading Up 6.1 %

Shares of OM opened at $3.91 on Thursday. The stock has a fifty day moving average price of $2.62 and a two-hundred day moving average price of $3.75. The company has a debt-to-equity ratio of 2.11, a quick ratio of 5.32 and a current ratio of 6.42. Outset Medical, Inc. has a 52-week low of $1.92 and a 52-week high of $24.13. The company has a market cap of $201.97 million, a price-to-earnings ratio of -1.16 and a beta of 1.85.

Outset Medical (NASDAQ:OM) last released its earnings results on Wednesday, February 21st. The company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.03). The firm had revenue of $30.51 million during the quarter, compared to analyst estimates of $30.40 million. Outset Medical had a negative net margin of 134.93% and a negative return on equity of 120.67%. Analysts predict that Outset Medical, Inc. will post -2.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on OM. BTIG Research began coverage on Outset Medical in a research note on Monday, April 8th. They set a “buy” rating and a $6.00 target price for the company. CL King raised Outset Medical from a “neutral” rating to a “buy” rating and set a $6.00 price objective for the company in a research note on Friday, April 5th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $5.42.

Outset Medical Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.